Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 20/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | HCK | P08631 | 1/20 | 1.00 |
| ▸ | FGR | P09769 | 1/20 | 1.00 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 1.00 |
| ▸ | FLT4 | P35916 | 1/20 | 1.00 |
| ▸ | KDR | P35968 | 1/20 | 1.00 |
| ▸ | MAP2K2 | P36507 | 1/20 | 1.00 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 1.00 |
| ▸ | RPS6KA1 | Q15418 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18518281 | 1.00 | RET (1.00) | RETCYP1A2HCKFGRRPS6KB1 | |
| SCHEMBL18518387 | 0.96 | RET (1.00) | RETCYP1A2HCKFGRRPS6KB1 | |
| SCHEMBL18518263 | 0.95 | RET (1.00) | RETCYP1A2HCKFGRRPS6KB1 | |
| SCHEMBL31639354 | 0.88 | RET (0.79) | RETCYP1A2HCKFGRRPS6KB1 | |
| SCHEMBL18518591 | 0.85 | RET (1.00) | RETCYP1A2HCKFGRRPS6KB1 | |
| SCHEMBL18518260 | 0.83 | RET (1.00) | RETCYP1A2HCKFGRRPS6KB1 | |
| SCHEMBL31639590 | 0.82 | RET (0.73) | RETCYP1A2HCKFGRRPS6KB1 | |
| SCHEMBL21178774 | 0.81 | RET (1.00) | RETCYP1A2HCKFGRRPS6KB1 | |
| SCHEMBL21178776 | 0.81 | RET (1.00) | RETCYP1A2HCKFGRRPS6KB1 | |
| SCHEMBL21179082 | 0.81 | RET (1.00) | RETCYP1A2HCKFGRRPS6KB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4665720-A2 | ISOINDOLINONE GLUTARIMIDE AND PHENYL GLUTARIMIDE ANALOGS AS DEGRADERS OF RET KINASE | Bristol-Myers Squibb Company (US) | 2025-12-24 | — | — | EP | disclosed |
| WO-2025137605-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF PROTO-ONCOGENE TYROSINE PROTEIN KINASE RECEPTOR | C4 THERAPEUTICS, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| WO-2024173832-A2 | ISOINDOLINONE GLUTARIMIDE AND PHENYL GLUTARIMIDE ANALOGS AS DEGRADERS OF RET KINASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-08-22 | — | — | WO | disclosed |
| CN-118319866-A | Formulations comprising RET kinase inhibitors | 罗索肿瘤学公司 | 2024-07-12 | — | — | CN | disclosed |
| CN-111630054-B | Substituted pyrazolo [3,4-d ] pyrimidine compounds as RET kinase inhibitors | 奥瑞生物药品公司 | 2023-05-09 | — | — | CN | disclosed |
| CN-111971286-B | Substituted pyrrolo [2,3-d ] pyrimidine compounds as RET kinase inhibitors | 阿雷生物药品公司 | 2023-04-14 | — | — | CN | disclosed |
| CN-111278822-B | Crystalline forms | 阿雷生物药品公司 | 2022-10-21 | — | — | CN | disclosed |
| CN-111615514-B | Substituted pyrazolo [4,3-C ] pyridine compounds as RET kinase inhibitors | 奥瑞生物药品公司 | 2022-10-11 | — | — | CN | disclosed |
| CN-110267960-B | Substituted pyrazolo [1,5-a ] pyrazine compounds as RET kinase inhibitors | 阿雷生物药品公司 | 2022-04-26 | — | — | CN | disclosed |